Product for chronic healing
Chronic wounds affect 2% of the adult population in developed countries and few effective treatments exist. A chronic wound is a wound that does not heal in 6 weeks, in consequence, their healing can take a very long time, with consequent repercussions on the quality of life of patient and the financial aspect. It is therefore very important to develop a device able to reduce the healing time of these chronic wounds.
Regentis-Pharma is currently developing a medical device, containing the innovative peptide developed by Regentis-Pharma, for the treatment of chronic wounds.
The cutaneous aging is defined by a more or less significant imbalance between the mechanisms controlling the synthesis and the degradation of the extracellular matrix of the dermis.
The aging process is characterized by a reduction in the synthesis of extracellular matrix proteins (collagens, elastin, etc…) combined with an increase in the enzymes responsible for their degradation: the matrix metalloproteinases (MMP). This imbalance leads to several characteristic signs of an aging skin such as dryness and slackening of the skin (due to reduced elasticity of the dermis) as well as the appearance of wrinkles. The dermo-cosmetic product proposed by Regentis-Pharma helps to restore the balance between degradation and synthesis of the extracellular matrix, thus leading to a reduction in wrinkles.
To address all the problems related to cutaneous aging and to scientifically demonstrate the effectiveness of its innovative product, Regentis-Pharma has conducted and completed a comparative, multicentric, randomized, controlled and double-blind clinical trial on more than twenty women volunteers with marked wrinkles. These volunteers have applied this anti-aging product twice daily for a period of 28 days.